LB Pharmaceuticals Inc.

LB Pharmaceuticals Inc. (Nasdaq: LBRX) is a clinical-stage biopharmaceutical company developing treatments for neuropsychiatric disorders. Its lead candidate, LB-102, is an oral small-molecule antipsychotic in Phase 3 development for schizophrenia and Phase 2 development for bipolar depression; the company also plans to evaluate it as an adjunctive treatment for major depressive disorder. LB-102 is a methylated, patent-protected derivative of amisulpride, designed to retain activity at dopamine D2 and D3 and serotonin 5-HT7 receptors while improving brain penetration and enabling lower-dose, once-daily treatment. The company is also developing a long-acting injectable formulation. Its broader development plans include potential applications in negative symptoms and cognitive impairment associated with schizophrenia, as well as other neuropsychiatric conditions. LB Pharmaceuticals focuses its business on developing LB-102 and reports no separate operating segments in the information provided. It owns global rights to the candidate and intends to retain U.S. commercialization rights, with potential commercial partners outside the United States.